OSMOTICA PHARMACEUTICALS PLC
NASDAQ
US Flag
OSMT

OSMT
OSMOTICA PHARMACEUTICALS PLC
US Flag
NASDAQ
 
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E

OSMT Stock Chart

Recent

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 466
Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company. The Company is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The Company is focused on progressing Phase III candidates under clinical development Ontinua ER and RVL-1201. It has developed Ontinua ER using its proprietary Osmodex drug delivery system. Ontinua ER has been designated by the FDA as an Orphan Drug in this indication. The Company is conducting a second Phase III clinical trial of RVL-1201 for droopy eyelid. The Company’s promoted products include specialty neurology drugs, such as Lorzone and ConZip for pain management, as well as women's health products, such as Divigel for menopause and the OB Complete family of prescription prenatal dietary supplements. The Company’s non-promoted products portfolio include methylphenidate ER and VERT as well as smaller volume ANDAs and prescription dietary supplements.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing TradingView Coins My Support Tickets Get Help Ideas Published Followers Following Private Messages Chat Sign Out